Biovaxys Technology Corp (TSE:BIOV) has released an update.
BioVaxys Technology Corp. has received a U.S. patent allowance for a low dose vaccine delivery system using their DPX platform, which enhances immune responses. The patent acquisition, initially from IMV Inc., supports their novel approach to cancer immunotherapeutics and therapeutic vaccines. Additionally, BioVaxys has initiated international patent filings for their DPX SurMAGE immunotherapy, showing promise in a Canadian Phase I clinical trial for bladder cancer.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
